Pertussis is an endemic disease in the EU/EEA and worldwide. Every three to five years, larger epidemics are expected even with high vaccination coverage.
Following the occurrence of several hospital-acquired malaria cases in the European Union (EU), ECDC has assessed the risk related to transmission of the parasite in hospital settings.
This Rapid Risk Assessment focuses on acellular pertussis-containing combination vaccines used in national vaccination programmes in the EU/EEA Member States.
This rapid risk assessment assesses the specific risk related to importation and spread of vector borne diseases in the context of a large number of migrants to the EU. It does not cover other health needs for these populations.
Early in 2015, a shortage of acellular pertussis-containing vaccines was brought to the attention of ECDC. This risk assessment provides a detailed list of mitigation options available to Member States.
ECDC and EFSA have assessed the risk to the EU/EEA posed by a fatal human case of Bacillus anthracis infection in Bulgaria and concluded that this event represents a negligible risk to other EU/EEA countries.
Locally acquired cases of malaria have been occurring in Greece since 2009, with the highest numbers reported in 2011. In 2012, local malaria transmission was still ongoing, but fewer cases were reported.
This is an update to the joint rapid risk assessment published on 6 July 2012 by ECDC and EMCDDA on anthrax cases among injecting drug users in Germany. This is in response to further cases in France and Denmark. It contains information updated up to the 13 July 2012.
This is an update to the joint rapid risk assessment published on 22 June 2012 by ECDC and EMCDDA on anthrax cases among injecting drug users in Germany. This is in response to a third case in Berlin. It contains information updated up to the 6 July 2012.